Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.

Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S.

Cancer. 2009 Dec 1;115(23):5490-8. doi: 10.1002/cncr.24632.

2.

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H.

J Clin Oncol. 2013 Feb 20;31(6):676-83. doi: 10.1200/JCO.2012.46.2309. Epub 2012 Nov 19.

3.

Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.

Silverman JA, Reynolds L, Deitcher SR.

J Clin Pharmacol. 2013 Nov;53(11):1139-45. doi: 10.1002/jcph.155. Epub 2013 Aug 17.

PMID:
23907766
4.

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.

Shah NN, Merchant MS, Cole DE, Jayaprakash N, Bernstein D, Delbrook C, Richards K, Widemann BC, Wayne AS.

Pediatr Blood Cancer. 2016 Jun;63(6):997-1005. doi: 10.1002/pbc.25937. Epub 2016 Feb 17.

PMID:
26891067
5.

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.

Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F.

Br J Haematol. 2013 Sep;162(5):631-8. doi: 10.1111/bjh.12446. Epub 2013 Jun 27.

PMID:
23802738
6.

Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.

Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H.

Cancer. 2006 Jan 1;106(1):120-7. Erratum in: Cancer. 2006 Apr 1;106(7):1641.

7.

Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.

Kaplan LD, Deitcher SR, Silverman JA, Morgan G.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):37-42. doi: 10.1016/j.clml.2013.09.009. Epub 2013 Oct 1.

PMID:
24252360
8.

Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.

Yan Z, Zhu ZL, Qian ZZ, Hu G, Wang HQ, Liu WH, Cheng G.

Acta Pharmacol Sin. 2012 Jun;33(6):852-8. doi: 10.1038/aps.2012.44.

9.

Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.

Silverman JA, Deitcher SR.

Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64. doi: 10.1007/s00280-012-2042-4. Epub 2012 Dec 5. Review.

10.

Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.

Steinherz PG, Shukla N, Kobos R, Steinherz L.

Pediatr Blood Cancer. 2010 May;54(5):687-93. doi: 10.1002/pbc.22321.

PMID:
20205253
11.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
12.

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.

Raj TA, Smith AM, Moore AS.

Int J Nanomedicine. 2013;8:4361-9. doi: 10.2147/IJN.S54657. Epub 2013 Nov 6. Review. Erratum in: Int J Nanomedicine. 2013;8:4705.

13.

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.

Davis T, Farag SS.

Int J Nanomedicine. 2013;8:3479-88. doi: 10.2147/IJN.S47037. Epub 2013 Sep 16. Review.

14.

Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.

Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G.

Br J Haematol. 2014 Nov;167(3):356-65. doi: 10.1111/bjh.13050. Epub 2014 Jul 26.

15.

High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.

Deitcher OR, Glaspy J, Gonzalez R, Sato T, Bedikian AY, Segarini K, Silverman J, Deitcher SR.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):197-202. doi: 10.1016/j.clml.2013.10.012. Epub 2013 Nov 15.

PMID:
24417913
16.

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.

Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H.

Cancer. 2010 Oct 1;116(19):4580-9. doi: 10.1002/cncr.25319.

17.

Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.

Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):54-9. doi: 10.3816/CLML.2011.n.007.

PMID:
21454191
18.

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.

Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G.

Am J Hematol. 2015 Feb;90(2):120-4. doi: 10.1002/ajh.23886. Epub 2014 Nov 19.

19.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M.

Clin Cancer Res. 2015 Jun 15;21(12):2704-14. doi: 10.1158/1078-0432.CCR-14-2888. Epub 2015 Feb 27.

20.

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC.

J Clin Oncol. 2011 Mar 10;29(8):979-85. doi: 10.1200/JCO.2010.30.5961. Epub 2011 Jan 31.

Supplemental Content

Support Center